Back

Lipoprotein(a) variability in high CV risk patients with hypertriglyceridemia and controlled LDL-C on statin therapy – REDUCE-IT Lp(a) Variability

28 August 2026 (10:55 - 11:05)
Organised by: Logo
Congress Presentation Part of: New insights into lipid-lowering pharmacotherapy Lipid-Lowering Agents ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Professor Deepak Bhatt

Icahn School of Medicine at Mount Sinai, New York City (United States of America)

5 More presentations in this session

Presentation thumbnail
Safety, tolerability, pharmacokinetics and pharmacodynamics of HRS-1301, an oral PCSK9 inhibitor, in healthy participants: a first-in-human, randomized, double-blind, placebo-controlled phaseⅠtrial
Professor S. Zhong (Guangzhou, CN)
Abstract Slides
Presentation thumbnail
Efficacy of enlicitide across ESC cardiovascular risk categories in two CORALreef phase 3 trials
Doctor E. Stroes (Amsterdam, NL)
Abstract Slides
Presentation thumbnail
Evolocumab and risk of a first myocardial infarction: a prespecified analysis of the VESALIUS-CV trial
Doctor G. De Ferrari (Turin, IT)
Abstract Slides
Presentation thumbnail
Intra-coronary imaging before and after PCSK9 inhibition stratified by residual inflammatory risk: a serial imaging sub-study of YELLOW III
Doctor P. C Revaiah (New York, US)
Abstract Slides
Presentation thumbnail
ION775, a long-acting siRNA targeting APOC3: single-dose, 12-month results in participants with moderate hypertriglyceridemia
Professor S. Tsimikas (La Jolla, US)
Abstract Slides

Access the full session

Session thumbnail
New insights into lipid-lowering pharmacotherapy
Video

The Event

Event poster

ESC Congress 2026

28 August 2026 10:55 CET
You may be interested in
thumbnail
Congress Presentation
Variability of lipoprotein(a) levels in patients hospitalized in an emergency setting
24 April 2026
thumbnail
Congress Presentation
REDUCE-IT: outcomes by baseline statin type
28 August 2020
thumbnail
Congress Presentation
A randomized, placebo-controlled phase 3 study of plozasiran in patients with familial chylomicronemia syndrome: PALISADE - 1 year open label extension
30 August 2025
thumbnail
Congress Presentation
Differential associations of lipoprotein(a)-associated cholesterol and triglycerides with coronary plaque burden and vulnerability: a PROSPECT II substudy
28 August 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources